The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Non-Radiographic Axial Spondyloarthritis Therapeutic Market Grow Between 2026 And 2030?
The non-radiographic axial spondyloarthritis therapeutic market size has seen rapid growth in recent years. It is forecast to increase from $1.04 billion in 2025 to $1.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.9%. This historical growth can be attributed to factors such as increasing recognition of non-radiographic axial spondyloarthritis, limitations of conventional NSAID therapy, improved diagnostic criteria adoption, growing rheumatology specialty care access, and the expansion of biologic drug availability.
The non-radiographic axial spondyloarthritis therapeutic market is poised for significant expansion in the upcoming years. It is projected to attain a value of $1.72 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.6%. This anticipated growth is driven by factors such as the increased creation of next-generation biologics, the growing acceptance of JAK inhibitor treatments, a rising emphasis on individualized rheumatology care, the expansion of early-stage intervention protocols, and enhanced patient awareness and diagnosis rates. Noteworthy trends for the forecast period include a greater adoption of biologic disease-modifying therapies, increased utilization of IL-17 and TNF inhibitors, a heightened focus on early disease intervention, the broadening of targeted small molecule treatments, and an increased priority on long-term disease control.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24627&type=smp
What Major Factors Are Driving The Non-Radiographic Axial Spondyloarthritis Therapeutic Market Forward?
A rise in clinical trials is projected to fuel the expansion of the non-radiographic axial spondyloarthritis therapeutic market in the future. These trials are human-based research efforts designed to assess the safety, efficacy, and potential adverse reactions of medical therapies or procedures. The surge in clinical trials stems from a rising need for tailored and novel treatments, which necessitate stringent safety and efficacy evaluations. For non-radiographic axial spondyloarthritis therapeutics, clinical trials offer evidence-backed confirmation of treatment effectiveness and safety during the early stages of the disease, thereby facilitating regulatory clearances and broader medical acceptance. As an illustration, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based entity dedicated to enhancing patient access to new treatments, indicated that the overall count of industry-led clinical trials started in the UK rose from 411 trials in 2022 to 426 in 2023. Consequently, the expansion of clinical trials is stimulating growth within the non-radiographic axial spondyloarthritis therapeutic market.
How Is The Non-Radiographic Axial Spondyloarthritis Therapeutic Market Organized By Segment Classification?
The non-radiographic axial spondyloarthritis therapeutic market covered in this report is segmented –
1) By Type: Non-Steroidal Anti-Inflammatory Drugs, Biologics, Small Molecule Therapies, Corticosteroids
2) By Application: Oral, Injectable, Parenteral
3) By End User: Hospitals, Ambulatory Surgical Centers, Homecare Settings
Subsegments:
1) By Non-Steroidal Anti-Inflammatory Drugs: COX-2 Inhibitors, Non-Selective NSAIDs
2) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-17 (IL-17) Inhibitors
3) By Small Molecule Therapies: Janus Kinase (JAK) Inhibitors, TYK2 Inhibitors
4) By Corticosteroids: Oral Corticosteroids, Intra-Articular Corticosteroid Injections
Which Trends Are Impacting The Progress Of The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
Leading companies active in the non-radiographic axial spondyloarthritis (nr-axSpA) therapeutic market are concentrating on developing innovative solutions, such as dual IL-17A/IL-17F biologic inhibitors and convenient delivery formats. This focus aims to address increasing diagnosis rates, earlier disease identification, the demand for quicker and more profound inflammatory control, and patient preferences for less frequent or more accessible dosing. These dual IL-17A/IL-17F biologic inhibitors employ monoclonal antibodies that specifically and concurrently block the cytokines IL-17A and IL-17F, which aids in managing nr-axSpA by reducing inflammation, pain, stiffness, and structural progression. For instance, in September 2024, UCB S.A. (Union Chimique Belge Société Anonyme), a Belgium-based global biopharmaceutical company, launched BIMZELX in the U.S. for adults with active nr-axSpA following FDA approval. BIMZELX is a humanized IgG monoclonal antibody designed to neutralize both IL-17A and IL-17F, offering broader suppression of IL-17-mediated pathways compared with traditional TNF inhibitors or single-target IL-17 therapies. In addition to nr-axSpA, BIMZELX is also indicated for moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, thereby addressing the evolving treatment needs of patients with inflammatory diseases.
Who Are The Industry Participants Involved In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
Major companies operating in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc, Johnson and Johnson, AbbVie Inc, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc, Biogen Inc, Daiichi Sankyo Company Limited, UCB SA, Mochida Pharmaceutical Co Ltd, Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co Ltd, Qyuns Therapeutics Co Ltd, Sandoz Group AG, Boehringer Ingelheim GmbH, Roche Holding AG
Get The Full Non-Radiographic Axial Spondyloarthritis Therapeutic Market Report:
Which Region Accounts For The Largest Portion Of The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2025. The regions covered in the non-radiographic axial spondyloarthritis therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Non-Radiographic Axial Spondyloarthritis Therapeutic Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market 2026, By The Business Research Company
Diabetic Retinopathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report
Proliferative Diabetic Retinopathy Pdr Market Report
Diabetic Neuropathy Market Report
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model